Thus, ablation of Pin1 by ATO, especially when combined with longer half-life ATRA, along with AQP9 expression as a potential marker for ATO sensitivity, offers an exciting new non-toxic approach to overcome cancer drug resistance in solid tumors, as demonstrated by its safety and efficacy against APL. This evidence concerns the gene AQP9 and cancer.